亞盛醫藥-B(06855.HK)公佈Bcl-2/Bcl-xL抑制劑APG-1252聯合奧希替尼治療EGFR TKI耐藥非小細胞肺癌最新數據
格隆匯9月9日丨亞盛醫藥-B(06855.HK)發佈公吿,公司在2021年世界肺癌大會(WCLC)上,已以小型口頭報吿形式(Mini Oral Session)公佈了原創雙靶點Bcl-2/ Bcl-xL抑制劑pelcitoclax (APG-1252)聯合奧希替尼治療EGFR TKI(人表皮生長因子受體酪氨酸激酶抑制劑)耐藥非小細胞肺癌(NSCLC)患者的Ib期臨牀研究成果。該項臨牀研究的主要研究者、中山大學腫瘤防治中心張力教授為報吿人。
根據披露,WCLC是由國際肺癌研究協會(IASLC)組織的世界上最大的致力於肺癌和其他胸部惡性腫瘤的多學科腫瘤學會議,聚焦該領域最前沿的科研與臨牀進展。亞盛醫藥在本次大會上公佈的是一項APG-1252聯合奧希替尼治療晚期EGFR突變陽性NSCLC患者的單臂、多中心、Ib期的劑量探索和劑量擴展臨牀研究,旨在評估APG-1252聯合奧希替尼治療的藥代動力學(PK)、安全性和初步療效。
APG-1252為亞盛醫藥自主研發的新型Bcl-2/Bcl-xL雙靶點抑制劑,可通過同時選擇性抑制Bcl-2及Bcl-xL蛋白修復細胞凋亡。在治療EGFR突變型NSCLC的臨牀前動物實驗模型中,APG-1252聯合奧希替尼對於奧希替尼敏感或耐藥模型均顯示出協同抗腫瘤作用。因此,APG-1252聯合奧希替尼有可能為這部分患者提供新的治療選擇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.